RT Journal Article
T1 Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
A1 Godoy-Ortiz, Ana
A1 Sánchez-Muñoz, Alfonso
A1 Chica Parrado, María del  Rosario
A1 Álvarez-Pérez, Martína
A1 Ribelles, Nuria
A1 Rueda-Domínguez, Antonio
A1 Alba-Conejo, Emilio
K1 Mamas - Cáncer
K1 Cáncer - Aspectos genéticos
AB The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers.
PB Frontiers Media
YR 2019
FD 2019
LK https://hdl.handle.net/10630/31230
UL https://hdl.handle.net/10630/31230
LA eng
NO Godoy-Ortiz A, Sanchez-Muñoz A, Chica Parrado MR, Álvarez M, Ribelles N, Rueda Dominguez A, Alba E. Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front Oncol. 2019 Oct 29;9:1124. doi: 10.3389/fonc.2019.01124. PMID: 31737566; PMCID: PMC6828840.
NO Este articulo ha sido publicado en la revista Frontiers in Oncology. Esta versión tiene Licencia Creative Commons CC-BY
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 3 mar 2026